MX2021006102A - Suministro mejorado de agentes grandes. - Google Patents

Suministro mejorado de agentes grandes.

Info

Publication number
MX2021006102A
MX2021006102A MX2021006102A MX2021006102A MX2021006102A MX 2021006102 A MX2021006102 A MX 2021006102A MX 2021006102 A MX2021006102 A MX 2021006102A MX 2021006102 A MX2021006102 A MX 2021006102A MX 2021006102 A MX2021006102 A MX 2021006102A
Authority
MX
Mexico
Prior art keywords
improved delivery
large agents
agents
delivery
improved
Prior art date
Application number
MX2021006102A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan Edelson
Original Assignee
Eirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirion Therapeutics Inc filed Critical Eirion Therapeutics Inc
Publication of MX2021006102A publication Critical patent/MX2021006102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021006102A 2018-12-03 2019-11-26 Suministro mejorado de agentes grandes. MX2021006102A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862774677P 2018-12-03 2018-12-03
US201962789407P 2019-01-07 2019-01-07
US201962808274P 2019-02-20 2019-02-20
PCT/US2019/063351 WO2020117564A1 (en) 2018-12-03 2019-11-26 Improved delivery of large agents

Publications (1)

Publication Number Publication Date
MX2021006102A true MX2021006102A (es) 2021-09-21

Family

ID=68966029

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021006102A MX2021006102A (es) 2018-12-03 2019-11-26 Suministro mejorado de agentes grandes.
MX2025005302A MX2025005302A (es) 2018-12-03 2021-05-25 Suministro mejorado de agentes grandes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025005302A MX2025005302A (es) 2018-12-03 2021-05-25 Suministro mejorado de agentes grandes

Country Status (12)

Country Link
US (1) US20220031595A1 (enExample)
EP (1) EP3890704A1 (enExample)
JP (2) JP2022510007A (enExample)
KR (1) KR20210102301A (enExample)
CN (2) CN113423381A (enExample)
AU (2) AU2019391791A1 (enExample)
BR (2) BR112021009554A2 (enExample)
CA (1) CA3119043A1 (enExample)
IL (1) IL283627A (enExample)
MX (2) MX2021006102A (enExample)
SG (1) SG11202104838SA (enExample)
WO (1) WO2020117564A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide
KR20230024669A (ko) * 2021-08-12 2023-02-21 주식회사 페로카 마이크로니들 패치
CN114191376B (zh) * 2022-01-05 2024-03-01 中国药科大学 一种用于治疗阿尔兹海默症的微针贴片及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US7384918B2 (en) 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
BRPI0608091A2 (pt) 2005-03-03 2009-11-10 Revance Therapeutics Inc composições e processos para aplicação tópica e distribuição transdérmica de um oligopeptìdeo
CA2642182A1 (en) * 2006-02-17 2007-08-30 Zogenix, Inc. Method and system for delivery of neurotoxins
US8658391B2 (en) 2006-04-27 2014-02-25 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
WO2010056922A2 (en) * 2008-11-12 2010-05-20 Kythera Biopharmaceuticals, Inc. Systems and methods for delivery of biologically active agents
EP2355887B1 (en) * 2008-11-18 2017-08-02 3M Innovative Properties Company Hollow microneedle array
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
BR112012030619A2 (pt) * 2010-06-01 2019-09-24 Novartis Ag concentração de antígenos de vacina influenza sem liofilização.
TR201905477T4 (tr) 2011-01-24 2019-05-21 Anterios Inc Nano-parçacık bileşimler.
SG10201804552WA (en) 2011-01-24 2018-07-30 Anterios Inc Nanoparticle compositions, formulations thereof, and uses therefor
WO2013096026A1 (en) 2011-12-21 2013-06-27 3M Innovative Properties Company Transdermal adhesive patch assembly with removable microneedle array and method of using same
EP3068423A1 (en) * 2013-11-12 2016-09-21 Finzi, Eric Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
US20170209553A1 (en) * 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
EP3491129A4 (en) * 2016-07-29 2020-01-22 Roger L. Kaspar METHODS OF TREATING OSMIDROSIS
KR102487144B1 (ko) * 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
CN107320841A (zh) * 2017-08-03 2017-11-07 党明 一种高分子微针及其制备方法和应用

Also Published As

Publication number Publication date
CN113423381A (zh) 2021-09-21
AU2019391791A1 (en) 2021-06-03
AU2025226856A1 (en) 2025-10-23
EP3890704A1 (en) 2021-10-13
SG11202104838SA (en) 2021-06-29
US20220031595A1 (en) 2022-02-03
MX2025005302A (es) 2025-06-02
IL283627A (en) 2021-07-29
CA3119043A1 (en) 2020-06-11
CN119700637A (zh) 2025-03-28
KR20210102301A (ko) 2021-08-19
WO2020117564A1 (en) 2020-06-11
BR122023023068A2 (pt) 2024-02-20
JP2024170568A (ja) 2024-12-10
JP2022510007A (ja) 2022-01-25
BR112021009554A2 (pt) 2021-08-17

Similar Documents

Publication Publication Date Title
ZA201906822B (en) Indole ahr inhibitors and uses thereof
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2019005833A (es) Administracion transdermica de agentes grandes.
PH12018501656A1 (en) Methods for using fxr agonists
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
MY205416A (en) Tyk2 inhibitors and uses thereof
MX2022004304A (es) Agentes inductores de apoptosis.
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
GB2541571A (en) Pharmaceutical compositions
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2022003967A (es) Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).
MX2021006326A (es) Inhibidores de pcna.
MX2025010681A (es) Formulaciones transdermicas
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.